New injection could help sleep apnea without CPAP

NCT ID NCT07387094

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests an injectable drug called XW003 (Ecnoglutide) in 140 obese adults with obstructive sleep apnea who do not use CPAP machines. The goal is to see if the drug reduces breathing pauses during sleep and helps with weight loss. Participants receive either the drug or a placebo for several months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

XW003 (Ecnoglutide) injection

What this could lead to

If successful, this could offer a drug-based option to reduce sleep apnea severity and body weight without needing a CPAP machine.

What could go wrong

This is still an experimental drug in a mid-sized trial. It may not work for everyone, and side effects like nausea or digestive issues are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder obstructive sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking University People's Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••